Takeda-Abbott Deal To Split TAP Followed Several Failed Attempts
This article was originally published in PharmAsia News
The deal with Abbott Laboratories to end their TAP Pharmaceutical Products partnership leaves Takeda Pharmaceuticals with a cash trove intact to buy a bigger firm. Abbott, a U.S. firm, came around to the split after it failed to sell its diagnostic machine arm to General Electric just over a year ago. Takeda was under pressure to make the deal because two of its major drugs, Prevacid (lansoprazole) for ulcers and Actos (pioglitazone hydrochloride) for diabetes, are due to lose their patent protection soon. Takeda plans to garner increased proficiency by merging TAP's sales and development arms with Takeda's other U.S. subsidiaries. (Click here for more - a subscription may be required
You may also be interested in...
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.